Traditional MedicarePrior AuthMedium impact
Ruconest (C1 esterase inhibitor, recombinant) (Revised)
Humana·KY, SC · Allergy & Immunology, Internal Medicine, Pharmacy·Medicaid
Effective date
Jan 1, 2025
We identified it
Jul 23, 2026
Summary
Humana has updated its Ruconest (C1 esterase inhibitor, recombinant) prior authorization policy effective January 1, 2025, with a revision dated July 22, 2026. This policy applies to Medicare, Medicaid-Kentucky, and Medicaid-South Carolina. The policy requires prior authorization for acute HAE attack treatment with eight specific approval criteria, including HAE diagnosis confirmation with lab documentation, specialist treatment requirement, and step-therapy waiver for Medicaid (but applies to Medicare Part B). Billing teams must ensure all prior authorization requirements are met before claims are submitted to avoid denials.
Action Required
By January 1, 2025: Billing team must implement prior authorization workflow for Ruconest (C1 esterase inhibitor, recombinant) claims. Specifically: (1) Configure billing system to require prior authorization submission for all Ruconest requests affecting Medicare Part B and Medicaid-Kentucky and Medicaid-South Carolina members; (2) Create pre-authorization checklist requiring documentation of: HAE Type 1 or Type 2 diagnosis, C4 level, C1INH antigenic/functional level OR known HAE-causing C1INH mutation, C1q level, history of recurrent angioedema without urticaria, specialist treatment (allergist/immunologist), and acute attack indication; (3) For Medicare Part B: Require documentation of prior icatibant trial/failure/contraindication before approval (step-therapy applies); (4) For Medicaid: Remove step-therapy requirement—approve based on clinical criteria alone; (5) Update provider encounter forms and prior auth request templates to capture all eight required approval criteria; (6) Train billing and clinical staff on distinction between Medicare Part B (step-therapy required) and Medicaid (step-therapy waived) requirements; (7) Notify in-network providers of new authorization requirements. Claims submitted without complete prior authorization documentation will be denied. Effective date: January 1, 2025.